SEC Comment Letter 0000000000-23-013268 to Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362) (LEXX)
Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)
Date: Dec. 6, 2023 · CIK: 0001348362 · Accession: 0000000000-23-013268
AI Filing Summary & Sentiment
File numbers found in text: 333-275810
Letter
United States securities and exchange commission logo December 6, 2023 Christopher Bunka Chairman and Chief Executive Officer Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia VIX 2P7 Re:Lexaria Bioscience Corp. Registration Statement on Form S-1 Filed November 30, 2023 File No. 333-275810 Dear Christopher Bunka: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Avital Perlman, Esq.
Show Raw Text
United States securities and exchange commission logo
December 6, 2023
Christopher Bunka
Chairman and Chief Executive Officer
Lexaria Bioscience Corp.
#100 – 740 McCurdy Road
Kelowna, British Columbia VIX 2P7
Re:Lexaria Bioscience Corp.
Registration Statement on Form S-1
Filed November 30, 2023
File No. 333-275810
Dear Christopher Bunka:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Avital Perlman, Esq.